Cytotoxic agents comprising maytansinoids and their therapeutic use
AssigneeImmunoGen, Inc.
InventorsRavi J. Chari, Victor S. Goldmacher, John M. Lambert, Walter A. Blattler
Life of this patent
Estimating the term…
Loading patent…
AssigneeImmunoGen, Inc.
InventorsRavi J. Chari, Victor S. Goldmacher, John M. Lambert, Walter A. Blattler
Estimating the term…
A cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. A therapeutic agent for killing selected cell populations comprising: (a) a cytotoxic amount of one or more maytansinoids linked to a cell binding agent, and (b) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting a cell population or tissue suspected of containing cells from said selected cell population with a cytotoxic amount of a cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. An N-methyl-alanine-containing ester of maytansinol or an analogue of maytansinol, said N-methyl-alanine-containing ester comprising a linking group capable of linking an N-methyl-alanine-containing maytansinoid ester to a chemical moiety. N-methyl-cysteine-containing ester of maytansinol or an analogue of maytansinol.
A cytotoxic agent comprising one or more maytansinoids linked to a hormone or growth factor via a linking group comprising a disulfide group.
Dependencies are inferred from the claim text.